A study demonstrating that GI Longevity’s independently developed probiotics (GB102) enhance weight loss efficacy when taken with GLP-1-based obesity treatments—and mitigate the yoyo effect as well as blood sugar rebounds after discontinuation—has been published in an international academic journal.

The company stated that after evaluating various probiotic candidates using obese mouse models, GB102 alone demonstrated efficacy in inhibiting weight gain and regulating blood sugar. In particular, when combined with GLP-1 obesity medication in obese mice, the weight loss effect was further enhanced compared to GLP-1 monotherapy, and a significant increase in whole-body energy expenditure was confirmed without causing muscle loss.

Based on these achievements, GI Longevity actively plans to pursue commercialization across various sectors, including health functional foods and metabolic disease solutions.

Read more: https://www.hankyung.com/article/202604140124i